Company / Current Assets
Lineage Cell Therapeutics, Inc. Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$59.2M
FY2025
5-year range
$38.4M / $111.5M
FY2021-FY2025
Trend
+16.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 10 years, ranging from $26M in FY2016 to $112M in FY2021.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of +6.1%.
Improved from $38M to $59M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -0.5%
- 5-Year CAGR
- +6.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.1%, indicating consistent growth.
- In FY2025, current assets increased 16.0% year-over-year.
- Peak current assets was recorded in FY2021.
- Lowest current assets in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.2M | +16.0% |
| FY2024 | $51.0M | +32.7% |
| FY2023 | $38.4M | -35.9% |
| FY2022 | $60.0M | -46.2% |
| FY2021 | $111.5M | +153.5% |
| FY2020 | $44.0M | -23.5% |
| FY2019 | $57.5M | +58.2% |
| FY2018 | $36.4M | -14.7% |
| FY2017 | $42.6M | +66.2% |
| FY2016 | $25.6M | -45.7% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026